Hemogenyx Pharmaceuticals (LON:HEMO) Hits New 52-Week Low – Should You Sell?

Shares of Hemogenyx Pharmaceuticals Plc (LON:HEMO) hit a new 52-week low during trading on Wednesday . The stock traded as low as GBX 184 ($2.38) and last traded at GBX 188.40 ($2.44), with a volume of 168652 shares traded. The stock had previously closed at GBX 196.50 ($2.54).

Hemogenyx Pharmaceuticals Trading Down 4.1 %

The company has a debt-to-equity ratio of 90.87, a current ratio of 4.38 and a quick ratio of 6.72. The stock has a market capitalization of £6.72 million, a PE ratio of -963.77 and a beta of 3.14. The stock’s 50 day simple moving average is GBX 348.35 and its two-hundred day simple moving average is GBX 157.34.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.